To address this liability, here we evaluate a novel allosteric c-Abl inhibitor, neurotinib, with high brain penetration at a low dose and found that AD mice fed with this inhibitor had reduced escape latency and required fewer trials to reach the learning criterion, improving the cognitive decline impairments seen in AD mice (Figure 2). The gene discussed is ABL1; the disease is Alzheimer disease.